drugset / Trial / NCT00528112

Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study

NCT00528112

Phase 3 Completed 2885 enrolled Bayer
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a study on a new low dose levonorgestrel contraceptive intrauterine systems (LCS). The purpose of the study is to investigate which of the 2 administered doses is the lowest effective intrauterine dose of Levonorgestrel (LNG) administered via the LCS for contraception during 3 years. The study was amended: the LCS16 arm will be extended up to 5 years

Timeline

Start
2007-08
Primary completion
2011-07
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 12 ug Other
Subject Levonorgestrel Small molecule 16 ug Other

Indications

No indication recorded.